MED
insider transactionsMEDIFAST INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
+5.0K
5.0K buy · 0 sell
Net value · 90d
$63.0K
$63.0K in · $0 out
Sentiment · 90d
Net buying
100% buying · 0% selling
Open-market trades · 90d
2
5.0K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
6.7K sh
Own +58%
-
Grant·A
Director
$0
11.7K sh
Own New
-
Grant·A
Director
$0
11.7K sh
Own +49%
-
Grant·A
Director
$0
11.7K sh
Own +38%
-
Grant·A
Director
$0
11.7K sh
Own +36%
-
Grant·A
Director
$0
7.6K sh
Own +65%
-
Grant·A
Director
$0
11.7K sh
Own New
-
Grant·A
Director
$0
11.7K sh
Own +60%
-
Buy·P
Director
$31.3K
2.5K sh · $12.53
Own +9%
-
Buy·P
Director
$31.6K
2.5K sh · $12.65
Own +10%
-
Grant·A
VP, Finance & CAO
$0
10.8K sh
Own +108%
-
Other·F
VP, Finance & CAO
$8.3K
862 sh · $9.59
Own -8%
-
Grant·A
James P. Maloney KEY
Chief Financial Officer
$0
1.0K sh
Own +1%
-
Grant·A
James P. Maloney KEY
Chief Financial Officer
$0
34.3K sh
Own +91%
-
Other·F
James P. Maloney KEY
Chief Financial Officer
$30.9K
3.2K sh · $9.59
Own -8%
-
Grant·A
Daniel R Chard KEY
Chairman & CEO
$0
4.8K sh
Own +3%
-
Grant·A
Daniel R Chard KEY
Chairman & CEO
$0
37.0K sh
Own +25%
-
Other·F
Daniel R Chard KEY
Chairman & CEO
$192.7K
20.1K sh · $9.59
Own -12%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 26, 2026 | Jeffrey Matthew Rose | Grant A | 6.7K | $0 |
| May 26, 2026 | Jeffrey Matthew Rose | Grant A | 11.7K | $0 |
| May 26, 2026 | Andrea B Thomas | Grant A | 11.7K | $0 |
| May 26, 2026 | Scott Schlackman | Grant A | 11.7K | $0 |
| May 26, 2026 | Ming Xian | Grant A | 11.7K | $0 |
| May 26, 2026 | Parsa Kiai | Grant A | 7.6K | $0 |
| May 26, 2026 | Parsa Kiai | Grant A | 11.7K | $0 |
| May 26, 2026 | Elizabeth A. Geary | Grant A | 11.7K | $0 |
| May 11, 2026 | Scott Schlackman | Buy P | 2.5K | $31.3K |
| May 8, 2026 | Scott Schlackman | Buy P | 2.5K | $31.6K |
| Mar 25, 2026 | Jonathan Barrett Mackenzie | Grant A | 10.8K | $0 |
| Mar 25, 2026 | Jonathan Barrett Mackenzie | Other F | 862 | $8.3K |
| Mar 25, 2026 | James P. Maloney KEY | Grant A | 1.0K | $0 |
| Mar 25, 2026 | James P. Maloney KEY | Grant A | 34.3K | $0 |
| Mar 25, 2026 | James P. Maloney KEY | Other F | 3.2K | $30.9K |
| Mar 25, 2026 | Daniel R Chard KEY | Grant A | 4.8K | $0 |
| Mar 25, 2026 | Daniel R Chard KEY | Grant A | 37.0K | $0 |
| Mar 25, 2026 | Daniel R Chard KEY | Other F | 20.1K | $192.7K |
About MED insider trading
This page tracks insider transactions for MEDIFAST INC (MED) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.